Enrico Capobianco Ph.D.
Lead Scientist, Center for Computational Science, University of Miami
Enrico Capobianco is an expert of complex systems with a wide experience at an international scale. He has explored the field of Biomedicine in multiple areas. He works as since 2012 a Lead Scientist at the Center for Computational Science, University of Miami, and collaborates with the Miller School of Medicine (Immunology, Dermatology, Neurology), the Bascom Palmer Eye Institute and the Sylvester Comprehensive Cancer Center.
He studied quantitative disciplines at LSE, London (1991-92), Northwestern University (1992) and UC Berkeley (Statistics, 1992-92; Mathematical Sciences Research Institute, 2003), Stanford (1994-1998, Computer Science, AI Lab ), Niels Bohr Institute and Danish Technical University (1999, NATO-CNR Fellow, Neurocomputing), CWI – Center for Mathematics and Computer Science, Amsterdam (2001-2001, ERCIM Fellow, Stochastics), Boston University (2004-2005, Biomedical Engineering), Serono, Evry (2005, Head of Methods), CRS4, Sardinia, Polaris Science & Tech Park (2006-11, Head of Quantitative Systems Biology Group, National Research Council, Institute of Clinical Physiology, Pisa (2012-2015, Founding PI of LISM – Laboratory of Integrative Systems Medicine; 2016-2017, Coordinator in Big Data in Health) .
He got professorships from CAS in China (2011, Shanghai) and Fiocruz Foundation (Rio, Brazil 2008-2010, Program, Capes – FIOCRUZ). His activities include includes multiple participation in academic programs at SAMSI, IMA, MSRI and IPAM Institutes in US, and visiting appointments at the International Centre for Theoretical Physics (Condensed Matter, 2003,Trieste), and at the Institut des Hautes Études Scientifiques (IHES) (Paris, 2010).
Enrico has been contributing to the growth of the field of Systems Medicine, especially leading Network Science towards both methodological advances and cancer applications. He is now focused on Precision Medicine, and particularly active in Computational Imaging and Big Data.
Beth Anne Baber Ph.D, MBA.
Co-Founder and CEO, The Nicholas Conor Institute
While Beth Anne was a cancer geneticist at the Salk Institute, her son, Conor, was diagnosed with neuroblastoma. She and her husband, a faculty member at The Scripps Research Institute, applied an evidence-base approach toward their son’s cancer care. Today, Conor is a healthy 13 year-old. Beth Anne co-founded The Nicholas Conor Institute, a non-profit aimed at advancing promising discoveries through the development pipeline. Armed with a background in research and business, she has become an effective patient advocate for pediatric cancers and rare diseases. She was instrumental in the establishment of $126M bi-partisan pediatric medical research initiative and generated funding for cancers of children, adolescents and young adults through the Department of Defense. In addition to being an advocate member of the Stand Up to Cancer Pediatric Cancers Dream Team, Beth Anne provided a voice for children and innovative patient engagement platforms during the development of the Precision Medicine and Cancer Moonshot Initiatives.
Brad Perkins, MD, MBA
Chief Medical Officer, Human Longevity
Dr. Perkins is a visionary physician, scientist, and executive who is responsible for leading all clinical and therapeutic operations at the HLI. This includes collecting and utilizing phenotype data, development of the consumer clinics business, and guiding stem cell therapeutics.
Prior to joining HLI, Dr. Perkins was Executive Vice President for Strategy and Innovation, and Chief Transformation Officer at Vanguard Health Systems, a large multi-state, for-profit, integrated health services provider with nearly 46,000 employees. He helped transform Vanguard from a traditional fee for service healthcare model, to a fee for value, “population health” model. Some of his innovative solutions there included: establishing Accountable Care Organizations to improve primary care, implementing an award winning tele-radiology program, and starting a $167 million venture capital fund to support Vanguard’s transformation programs.
Dr. Perkins began his career at the Centers for Disease Control and Prevention (CDC) in 1989 after completing his residency training and chief residency in internal medicine at Baylor College of Medicine. At the CDC he led some of the most important and high profile programs and published more than 120 peer-reviewed publications and book chapters.
He first joined and then led the Meningitis and Special Pathogens Branch where he investigated global bacterial disease epidemics. He co-discovered the bacteria which causes Cat Scratch Diseases and conducted translational research leading to development of several new bacterial meningitis and pneumonia vaccines. In 2001 Dr. Perkins led the investigations into the anthrax attacks in the United States, the largest and highest profile investigation ever conducted by CDC. In 2005 he was appointed CDC’s Chief Strategy and Innovation Officer, a position in which he managed a $11.2 billion budget, and 15,000 employees with offices in more than 50 countries. Working closely with the CDC Director, he built a $2 billion state-of-the-art emergency response capability and positioned the improvement of population health as a focus of the healthcare reform movement within the White House administration at that time.
Dr. Perkins is a member of the RAND Health Board, and he is the chairman of the advisory board for Esther Dyson’s nonprofit, HICCup, sponsor of the “Way to Wellville” community health competition. He received his BA in Microbiology and his MD from the University of Missouri-Columbia, and an MBA from Emory University. He is Board Certified in Internal Medicine.
David Ewing Duncan
Author & CEO Arc Fusion
David Ewing Duncan is an award-winning, best-selling author of nine books published in 21 languages. David is CEO and Curator of Arc Fusion, and a Health Strategist in Residence for IDEO. He is a columnist for the Daily Beast and the chief correspondent for NPR Talk’s Biotech Nation. David writes for The New York Times, Atlantic, Fortune, Wired, National Geographic, Discover, and Outside, among others. He is a former commentator for NPR’s Morning Edition and a special correspondent and producer for ABC’s Nightline and 20/20, a former producer for Discovery Channel, and a correspondent for NOVA’s ScienceNow!. His latest book is When I’m 164: The new science of radical life extension, and what happens if it succeeds (TED books). He also wrote Experimental Man: What One Man’s Body Reveals about His Future, Your Health, and Our Toxic World (Wiley). He is the founding director of the Center of Life Science Policy at UC Berkeley, and is on the faculty at Singularity University. David is finishing his first novel, a biomedical thriller. David’s work has won numerous awards, including Magazine Story of the Year from AAAS, and has been nominated twice for a National Magazine Award. He serves on a committee of the National Academies of Sciences. David lives in San Francisco and is a member of the San Francisco Writers’ Grotto.
Dana Hosseini, MBA
Co-Founder & CEO, ProdermIQ, Inc.
A serial entrepreneur who has managed and co-founded a number of genomics-based companies including, ProdermIQ, Iceland Genomics and DiThera. Mr. Hosseini’s skills in international medical device/diagnostic sales and market were developed at Abbott Laboratories, Ortho Clinical Diagnostics (Johnson & Johnson) and Sequenom where he held executive and management positions in business development, sales and marketing functions. He has 25+ years of extensive experience working with global biotech, pharmaceutical companies and healthcare providers. He received both his B.Sc. and MBA from the University of British Columbia.
Deputy Vice President of Policy & Research at PhRMA
Gretta Stone is deputy vice president of policy & research at PhRMA, where she works to communicate the positive contribution of biopharmaceutical companies and their products. She manages a range of issues related to the R&D process, FDA regulation, the value of medicines, and personalized medicine. Gretta has authored many PhRMA reports and publications including the annual Biopharmaceutical Industry Profile, an overview of the sector and a go-to source of data on the industry; the Setbacks and Stepping Stones series on medicines that do not make it to approval but pave the way for progress; and the Decade of Innovation series on advances in the fight against many diseases. In her more than twelve years at PhRMA she has also work extensively on orphan drugs, the biopharmaceutical pipeline, the research ecosystem, the cost of medicines, and marketing and promotion. Gretta also serves on the board of the Society for Women’s Health Research, an organization dedicated to advancing our understanding of the biological differences in disease and advocating to enhance women’s health. Prior to joining PhRMA, Gretta worked in a lab researching language and the brain at Georgetown University, where she received a BS in biology.
Reece Hart, Ph.D.
Chief Technology Office, Genome Medical, Inc.
Reece is Chief Technology Officer at Genome Medical, a nationwide medical practice providing a network of genetic counselors and clinicians who help customers to navigate genetic testing options and to understand genetic results. Genome Medical bridges the gap between genome technology and medical practice by serving both physicians and patients to move us toward a more genome-centered healthcare system. Prior to Genome Medical, he was a Research and Engineering Fellow at Invitae, Director of Engineering at 23andMe, and bioinformatics scientist and manager of research computing at Genentech. He is active leader and contributor to open source/open data efforts to facilitate genomic data sharing, including Global Alliance for Genomic Health, the Variation Modeling Collaboration, and Human Genome Variation Society nomenclature recommendations.
Mary E. Edgerton, M.D, Ph.D.
Associate Professor, Department of Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Mary E. Edgerton was born in Austin, Texas and was raised in the Rio Grande Valley. She received a B.S. in Physics with Highest Honors from the University of Texas at Austin. Following this, she was a Marshall Scholar to the United Kingdom where she received a Ph.D. in Biophysics from the University of East Anglia. She completed postdoctoral studies at the Unviersity of California at San Francisco and at the State university of New York at Stony Brook, and then worked for nine years for Exxon and then Mobil Oil Company in their research laboratories. She left the research laboratoires to attend medical school, and obtained her MD. from Medical College of Pennsylvania in Philadelphia. She completed her pathology residency and surgical pathology fellowship at the Hospital of the University of Pennsylvania. She is board certified in Anatomic and Clinical Pathology and was an Assistant Professor of Pathology at Vanderbilt University and an Associate Professor in the Division of Anatomic Pathology at the Moffitt Cancer Center before coming to MD Anderson, where she is currently an Associate Professor with tenure.
Laura Esserman, M.D., M.B.A.
Director of the Carol Franc Buck Breast Care Center, UCSF Medical School, professor of Surgery & Radiology, UCSF, and faculty at the UCSF Helen Diller Family Comprehensive Cancer Center
Dr. Laura Esserman, M.D., M.B.A is a surgeon and breast cancer oncology specialist practicing at the UCSF Carol Franc Buck Breast Care Center where she has also held the position of Director since 1996. She co-leads the Breast Oncology Program, the largest of the UCSF Helen Diller Comprehensive Cancer Center’s multidisciplinary programs. The program is comprised of 69 faculty members who represent 16 academic specialties and is internationally recognized and well-established with major initiatives in epidemiology, genetics, biology, therapeutics, and clinical cancer care. She is a professor of Surgery & Radiology at UCSF and faculty at the UCSF Helen Diller Family Comprehensive Cancer Center where she founded the program in Translational Informatics. As part of this program, her research has focused on bioinformatics, medical and clinical informatics, systems integration, and clinical care delivery.
She has worked at UCSF to develop interdisciplinary teams of clinicians and researchers to bring the best care to patients and find the best platform to integrate translational research and improve the delivery of breast cancer care. In 2005, she received the NCI SPORE Investigator of the Year Award, an internationally recognized honor and designation.
She is the Principle Investigator of the I-SPY TRIAL program, a multi-site neoadjuvant clinical trial that has evolved into a model for translational research and innovation in clinical trial design.
Dr. Esserman has recently launched a University of California-wide breast cancer initiative called the Athena Breast Health Network, a project designed to follow 400,000 women from screening through treatment and outcomes, incorporating the latest in molecular testing and web-based tools into the course of care.
Dr. Esserman is nationally and internationally known as a leader in the field of breast cancer and has published over 150 articles in peer-reviewed journals covering all aspects of breast health including information systems, immunology, decision making, health policy and the use of imaging. She speaks extensively at public and private forums within the U.S. and internationally. Overall, Dr. Esserman’s research and writing tends to focus on the goal of giving patients better access to accurate information so that they can become partners in their health care.
She is a member of President Obama’s Council of Advisors on Science and Technology (PCAST) Working Group on Advancing Innovation in Drug Development and Evaluation, which is studying how the federal government can best support science-based innovation in the process of drug development and regulatory evaluation. In addition, she is a contributing member of a “taskforce” for President Obama’s Council of Advisors on Science and Technology.
Dr. Esserman received her Bachelor’s degree in History of Science from Harvard University and completed her M.D. at Stanford University. She completed her surgery residency and oncology fellowship at Stanford University Medical Center. After her training, she joined the faculty at Stanford and received a Hartford fellowship to attend Stanford Business School where she received her M.B.A. in 1993. She then joined the faculty at the University of California, San Francisco.
Global Head of Janssen Diagnostics
Werner joined Johnson & Johnson in 1991 with the International Clinical R&D group of the Janssen Research Foundation, where he was active in HIV drug development and Hepatitis B vaccine development. In 1997, Werner joined Virco, as Project Director, Business Development. He was promoted to Managing Director, Virco Ireland in 2002 and became Vice President, New Products and Pharma Business.
He is currently Global Head Janssen Diagnostics, comprising the legacy organizations of Virco, Veridex and Johnson and Johnson’s Companion Diagnostics Center of Excellence. Over these years, he has been active in all phases of HIV clinical trial strategy and implementation, biomarker development (Collaborative Surrogate Marker Validation working groups with FDA and EMA), and has contributed to numerous papers and presentations on pharmacogenomics and personalized medicine.
In his current role as Global Head, Werner plays a leading role in advocating for and actualizing a personalized medicine approach within JnJ, but also outside JnJ, including several board seats in different “precision medicine” and Dx organizations.
David S. Karow, Ph.D., MD
Chief Medical Imaging Officer, Human Longevity, Inc.
David S. Karow, MD, PhD, Chief Medical Imaging Officer at HLI, is an innovative leader in the medical imaging space who brings more than 10 years of experience in advanced MR Imaging, focused on the development and translation into clinical care of diffusion-based MRI techniques. Dr. Karow is the Chief Radiologist at HLI’s Health Nucleus.
Before joining HLI, Dr. Karow was the Director of Body MRI within the Body Imaging Division and Director of Evening Acute Care Imaging in the Department of Radiology at University of California, San Diego (UC San Diego), where he still serves as Associate Professor, Health Sciences Clinical and Associate Director, Center for Translational Imaging and Precision Medicine. During his time at UC San Diego he, in collaboration with Dr. Anders Dale, PhD, Dr. Nate White, PhD and Dr. Joshua Kuperman, PhD in the Center for MultiModal Imaging and Genetics (CMIG), implemented a new, advanced diffusion method (RSI) that proved beneficial for the detection and in vivo characterization of prostate tumors. He worked to create a standard MRI protocol that is obtained on patients with proven or suspected prostate cancer. The protocol made it possible to obtain standardized, high quality quantitative imaging, which has greatly enhanced the ability to detect, localize and characterize prostate cancer. The work has yielded multiple published papers and led to multiple federal and private research grants on which Dr. Karow was Principal Investigator. Dr. Karow and collaborators continue to investigate using RSI-MRI as a biomarker for cervical cancer radiotherapy treatment response, and are compiling data showing that these techniques may be useful for the screening and staging of cancer across the whole body including breast cancer.
Dr. Karow completed his fellowship in advanced body imaging at University of California, Los Angeles (UC Los Angeles). Prior to entering the Fellowship program at UC Los Angeles, he completed his residency in diagnostic radiology at UC San Diego in the 5-year research residency pathway. His research during residency was recognized with several awards, including the 2011 Elliott C. Lasser Award for Excellence in Research; 2009 American Roentgen Ray Society Executive Council Award; the 2008 RSNA Trainee Research Prize; and his work was also featured on the cover of the September 2010 issue of the journal RADIOLOGY.
Martin Reese, Ph.D.
Founder, President & CEO, Fabric Genomics
Dr. Reese is an internationally recognized expert and entrepreneur in Genomics and Bioinformatics. Prior to founding Fabric Genomics, Martin served as Vice President of Discovery Informatics for ValiGen, and co-founded Neomorphic, where he served as President and Chief Scientific Officer. The human genome annotation software that Martin developed at Neomorphic, provided the foundation for the successful commercialization of microarrays by Affymetrix. During his career he has been actively involved in community-wide assessments of genome annotation. He organized the state-of-the-art Genome Annotation Assessment Project and was a member of the Berkeley Drosophila Genome Project, which provided the essential proof-of-concept platform for “shotgun” sequencing technology. At the Lawrence Berkeley National Laboratories Martin developed gene-finding algorithms for the Human Genome Project. He holds a Masters degree in Medical Informatics from the University of Heidelberg and a Ph.D. in Genetics jointly from the University of Hohenheim, Germany and UC Berkeley
President & CEO, BIOCOM
Joseph Panetta is President and CEO and a member of the Board of Directors of Biocom, California’s largest and most-experienced leader and advocate for the life science industry. Biocom works on behalf of more than 950 members to drive public policy, build an enviable network of industry leaders, create access to capital development, introduce cutting-edge STEM education programs, and create robust value-driven purchasing programs. As President and CEO, he works with an experienced professional staff of 50, with offices located in San Diego, Los Angeles, Tokyo, and Washington, D.C. Together with a 60-member Board of Directors, he leads initiatives that help members produce novel solutions that improve the human condition.
Mr. Panetta oversees several subsidiaries of Biocom, including a Purchasing Group that provides more than $100 million in products and services savings to members. He is co-founder of the Biocom Political Action Committee, the Biocom Institute for education and workforce development, and chairman of the California Biotechnology Foundation, a joint initiative to inform legislators and the media about the state’s life science sector. In 2014, Mr. Panetta was appointed by California Governor Jerry Brown to the Independent Citizens Oversight Committee, which serves as the governing and oversight board for the California Institute for Regenerative Medicine (CIRM) and is responsible for providing grant funding under the $3 billion California Stem Cell Initiative. He is past chairman of the Council of State Bioscience Associations (CSBA) and founding chairman of the State Medical Technology Alliance (SMTA)
Mr. Panetta holds a Bachelor of Science degree in biology from LeMoyne College, and a Master of Public Health degree in industrial and environmental health from the University of Pittsburgh. He is a graduate of the Brookings Institution Program for Executives and the Harvard Program on Negotiation. Mr. Panetta brings a depth of experience to his role, having worked in policy in Washington, D.C. and in regulatory affairs in the life science industry before joining Biocom in 1999.
Mr. Panetta serves on the boards of directors of the San Diego Regional Economic Development Corporation, the San Diego Regional Chamber of Commerce, and CONNECT. He is a past chairman of the board of the San Diego Workforce Partnership. Mr. Panetta is a member of advisory boards of the Pharmacy School at UC San Diego, the Engineering school at San Diego State University, the College of Science and Mathematics at Cal State University San Marcos, and the National University School of Business and Management. He has received the following awards: the American Academy of Pharmaceutical Physicians Special Recognition Award; the CONNECT Distinguished Contribution Award for Life Science Innovation; and the Association of Pan Asian Communities Annual Leadership award, among others.
Bernard Munos, MBA
Senior Fellow – Faster Cures & Founder, InnoThink Center for Research in Biomedical Innovation
Bernard Munos is a Senior Fellow at FasterCures, a center of the Milken Institute, and the founder of the InnoThink Center for Research in Biomedical Innovation, a consultancy that helps biomedical research organizations become better innovators. Before that, he served as an advisor for corporate strategy at Eli Lilly, where he focused on disruptive innovation and the radical redesign of R&D. He is also a member of the National Academy of Medicine’s Drug Forum; a member of the Advisory Board of Science Translational Medicine; a non-executive Director of Glenmark Pharmaceuticals; a Board member or Advisor to a dozen other companies or publicly-financed research organizations; and a former member of the Advisory Council of the National Institutes of Health’s National Center for Translational Sciences (NCATS). His research has been profiled by Forbes magazine; and the popular industry newsletter FiercePharma named him one of the 25 most influential people in biopharma. He received his MBA from Stanford University, and holds other graduate degrees in animal science and agricultural economics from the Paris Institute of Technology for Life, Food and Environmental Sciences and the University of California, Davis. He blogs about biomedical innovation on the Forbes website.
Managing Director and Global Head of Life Sciences Practice , Parthenon-EY,
Kristin is a Managing Director of Parthenon-EY and Global Head of the Life Sciences practice. Based in the Boston office, she has 20 years of experience in the life sciences sector. Kristin is serving clients in the pharmaceutical, biotech, diagnostics and life science tools industries, with a focus on company and investor commercial strategy and M&A support for diagnostics, life science research and pharmaceutical companies. She is also the creator and leader of EY Precision Medicine™.
Prior to joining EY in 2013, Kristin was a partner and owner of Health Advances, where she managed the firm with four other partners and developed and led a global Diagnostics and Life Sciences practice focused on product and service strategy, corporate strategy, health economics and deal diligence. She is also a founder of DxInsights, a nonprofit organization designed to educate the nation’s health care communities on the impact of diagnostics in improving health care outcomes.
Kristin earned a BA in Biochemistry from Smith College and an MS in Epidemiology, Health Management, and Maternal and Child Health from the Harvard School of Public Health.
David A. Shaywitz, MD, Ph.D.
Chief Medical Officer, DNAnexus
Dr. Shaywitz is the Chief Medical Officer of DNAnexus, where he focuses on product-market fit, working closely with the DNAnexus team of scientists and engineers, and with external partners and collaborators. Most recently at Theravance Biopharma, he focused on strategy, new product planning, and business development, and led a product team. Previously, he was a management consultant at the Boston Consulting Group, working with Top 5 Biopharma clients on both R&D and commercial engagements. Before that, he was an early member of the Department of Experimental Medicine at Merck Research Labs. Dr. Shaywitz was also a founding advisor of Sage Bionetworks, and a co-founder of the MGH/MIT Center for Assessment Technology and Continuous Health (CATCH). He has also served as a venture fellow at Fidelity Biosciences (now F-Prime Capital). He graduated summa cum laude from Harvard, received his MD from the Harvard-MIT Division of Health, Science, and Technology at Harvard Medical School, and his PhD from the Department of Biology at MIT. He trained in internal medicine and endocrinology at the Massachusetts General Hospital, and conducted his post-doctoral research in Doug Melton’s lab at the Harvard Stem Cell Institute. He currently serves as a visiting scholar (adjunct) in the Department of Biomedical Informatics at Harvard. He writes regularly for about medical innovation for Forbes, and contributes commentaries to a range of leading publications. He is co-author, with Lisa Suennen, of “Tech Tonics: Can Passionate Entrepreneurs Heal Healthcare With Technology?,” and co-hosts, with Lisa Suennen, the bimonthly Tech Tonics podcasts, focused on “the people and passion at the intersection of technology and health.”
Bernard Parker, MBA.
Managing Director, Caligen Bio
Bernard Parker is managing director at Caligen Bio, where he advises emerging life science companies on business development and commercialization strategy. Possessing two decades of pharmaceutical and biotech leadership in the U.S. and internationally, Bernard has led novel corporate, business unit, and product growth initiatives while holding influential leadership roles at innovative companies including Ignyta, Novartis, Amgen, and Bain & Co. Bernard was previously at San Diego-based biotech Ignyta, Inc., where he was responsible for commercial development of a portfolio of pre-clinical and clinical-stage precision oncology drug candidates. Before that, Bernard spent 5+ years at Novartis AG in Europe, where he initially focused on growing a Munich-based oncology biosimilars portfolio from zero to $100 million in revenues and later served as head of a $1 billion specialty pharmaceuticals franchise based in Geneva, Switzerland.
Prior to Novartis, Bernard was a management consultant at Bain & Company, where he focused on corporate strategy, commercial due diligence, and operational improvement. Earlier, he held sales and marketing roles at Amgen Oncology and Parke-Davis/Warner Lambert (now Pfizer). Bernard earned an M.B.A. from Harvard Business School and a B.A. in Biological Sciences magna cum laude from Hampton University. He conducted biomedical research at the National Institutes of Health, who granted him a Medical Scientist Training Program fellowship to pursue an M.D./Ph.D. at Baylor College of Medicine.
Richard Kronick, Ph.D.
Professor, Department of Family Medicine & Public Health, UCSD
Richard Kronick, PhD, a Professor in the Department of Family Medicine and Public Health at UC San Diego recently returned from a sabbatical in Washington D.C. where he served as Director of the Agency for Healthcare Research and Quality (AHRQ). He previously served as Deputy Assistant Secretary for Health Policy at Health and Human Services in Washington D.C. from 2010 – 2013. His work at UC San Diego focuses on understanding the causes and consequences of lack of insurance, and on understanding whether and how markets can be made to work in health care, particularly for vulnerable populations. He has developed and helped state Medicaid programs implement risk-adjusted payment systems for payment to HMOs.
Hudson Freeze, Ph.D.
Director and Professor, Human Genetics Program, Sanford Children’s Health Research Center, Sanford Burnham Prebys Medical Discovery Institute
Hudson H. Freeze, PhD, is a Professor of Glycobiology and Director of the Human Genetics Program at Sanford-Burnham Medical Research Institute (SBMRI) in La Jolla. Dr. Freeze is a Past President of the Society for Glycobiology and is the first representative from that Society to serve on the FASEB Board of Directors.
Dr. Freeze has earned nearly 40 years of continuous NIH funding in Glycobiology, beginning with his postdoctoral work. In the last 18 years he focused on the identification and understanding of human genetic disorders, the Congenital Disorders of Glycosylation (CDG), which now number over 100. He collaborates closely with physicians, families and their support organizations and regularly consults on cases while still tracking the genetic basis of multiple patients with unknown glycosylation defects.
Prior to his 25 years at SBMRI, Dr. Freeze was a member of the UCSD School of Medicine faculty, and continues there as an Adjunct Professor. He isolated the first extreme thermophile, Thermus aquaticus (Taq), for which he won the 2013 Golden Goose Award.
Standish Fleming, MBA
Managing Member, Forward Ventures
A 30-year veteran of early-stage venture capital investing, Mr. Fleming has helped raise and manage six venture funds totaling more than $500 million and has served on the boards of 19 venture-backed companies. He has extensive experience in all aspects of venture management and finance, including fundraising,
investor relations, operations and portfolio development. He has made investments, managed portfolio companies, raised funds, pursued business development, taken companies public and successfully exited investments through public-market sales and buyouts.
In 1993, Mr. Fleming co-founded Forward Ventures. He has made investments in almost every segment of the health-care industry, including pharmaceuticals, biologics, diagnostics, devices, services and software. He has managed both platform and product companies/investments in the portfolio and led or participated in financings at all levels from pre-start-up to PIPES in public companies, in both debt and equity. He has helped start more than 15 companies and served as founding CEO of eight.Mr. Fleming serves as a director of CONNECT, San Diego’s support organization for the academic-to-earlystage community, and is a past president of the Biotechnology Venture Investors Group. Before establishing Forward Ventures, He served as the chairman, president and CEO of GeneSys Therapeutics (merged with Somatix and acquired by Cell GeneSys [NASDAQ:CEGE]). He began his venture career with Ventana Growth Funds in San Diego in 1986. He earned his B.A. from Amherst College and his M.B.A. from the UCLA Graduate School of Management.
Edward Abrahams, Ph.D.
President, Personalized Medicine Coalition
Edward Abrahams, Ph.D., is the president of the Personalized Medicine Coalition (PMC). Representing innovators, scientists, patients, providers and payers, PMC promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system. It has grown from its original 18 founding members in 2004 to more than 225 today.
Previously, Dr. Abrahams was the executive director of the Pennsylvania Biotechnology Association, where he spearheaded the successful effort that led to the Commonwealth of Pennsylvania’s investment of $200 million to commercialize biotechnology in the state. Earlier, he had been assistant vice president for federal relations at the University of Pennsylvania and held a senior administrative position at Brown University.
Dr. Abrahams worked for seven years for the U.S. Congress, including as a legislative assistant to Senator Lloyd Bentsen, an economist for the Joint Economic Committee under the chairmanship of Representative Lee Hamilton, and as a AAAS Congressional Fellow for Representative Edward J. Markey.
The author of numerous essays, Dr. Abrahams serves on the editorial board of Personalized Medicine and has taught history and public policy at Brown University and the University of Pennsylvania.
PhD Candidate, University of Mississippi School of Pharmacy, Graduate Research Assistant, St. Jude Children’s Hospital
Nicholas Keeling has been a graduate research assistant with St. Jude Children’s Research Hospital for the past several years while working towards his PhD from the School of Pharmacy at the University of Mississippi. In his role at St. Jude, Nick works with Dr. James Hoffman, the Chief Patient Safety Officer and leader on the PG4KDS preemptive pharmacogenetics protocol.
Nick’s research thus far has focused on the translational science of pharmacogenetics and the preemptive testing model. Prominent academic health centers throughout the U.S. have implemented preemptive pharmacogenetic testing protocols. His work has been presented to several NIH sponsored multi-center research consortiums that support these protocols, such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) and Implementing GeNomics In pracTicE (IGNITE), as well as others with commercial interests. Nick looks forward to future work in developing health policy strategies for efficient implementation of genomic and other med tech innovations.
Prior to beginning his doctoral studies, Nick worked for several years in healthcare consulting focused on strategy and market access for new pharmaceuticals and medical devices. Nick holds a BA in Economics, BM in Classical Voice, and MS in Pharmaceutical Science from the University of Mississippi
Edward Tsai, MBA, MPH
Founder & CEO, Base Four
Edward Tsai is a precision medicine strategy executive focused on translating scientific advancements into revenue opportunities. Edward is the Founder and CEO of Base Four Inc., a precision medicine technology and consulting startup, specializing in strategy and data monetization.
Prior to launching Base Four, he led strategy for the precision medicine arm of Children’s Hospital Los Angeles and was a strategy consultant for PricewaterhouseCoopers (PwC) focused primarily in precision medicine. In these roles, he helped identify new markets, evaluate competitive environments, commercialize technologies, and develop business plans and financial models to capitalize on emerging trends in precision medicine; specifically, at the intersection of genetics, biotechnology, and digital technology.
Gregory Light, Ph.D.
Professor and Deputy Vice Chair of Education and Training in the UCSD Department of Psychiatry, UCSD
Dr. Gregory Light is a Professor and Deputy Vice Chair of Education and Training in the UCSD Department of Psychiatry. Dr. Light also serves as the Director of Mental Health Research and the Director of the Mental Illness, Research, Education and Clinical Center (MIRECC) at the VA San Diego Healthcare System. In these roles, he provide leadership, supervision, and administrative support across several clinical, education, and multidisciplinary research programs. Dr. Light has published over 120 peer-reviewed papers (h-index=49). This work has been prominently featured in policy reports from the Institute of Medicine for next-generation strategies for personalized treatments of psychotic disorders.
Kathryn A. Phillips, Ph.D.
Founding Director, Center for Translational and Policy Research on Personalized Medicine (TRANSPERS) in the School of Pharmacy Director, UCSF
Kathryn A. Phillips, PhD, a health services researcher and health economist and leader in the application of new technologies to improve healthcare, is the founding director of the Center for Translational and Policy Research on Personalized Medicine (TRANSPERS) in the School of Pharmacy at the University of California, San Francisco (UCSF). She is also a professor of health economics and health services research in the Department of Clinical Pharmacy at UCSF, with additional appointments in the UCSF Philip R. Lee Institute for Health Policy Studies and UCSF Helen Diller Family Comprehensive Cancer Center
Kathryn focuses on the value of new technologies and how to most effectively and efficiently implement them into health care. Her core specialty is personalized (or precision) medicine — a new era of healthcare where medical interventions can be tailored to individual patients based on their unique genetic make-up. Her work spans multiple disciplines, including basic, clinical and social sciences, and brings together leading experts in academia, industry, healthcare, payers, and government. Kathryn led one of the earliest studies on the societal implications of pharmacogenomics, underscoring its potential to reduce the incidence of adverse drug reactions (JAMA, 2001). Her pioneering research on the application of health services research to personalized medicine has revealed insights on how to bridge the gap between emerging technologies and their use in the clinic. Kathryn has also conducted seminal work on HIV, as her analysis of HIV home testing informed the FDA’s decision to approve the first home collection HIV test (New England Journal of Medicine, 1995).
Kathryn has published ~150 peer-reviewed articles in major journals, including JAMA, the New England Journal of Medicine, and Health Affairs and has had continuous funding from the US. National Institutes of Health as a principal investigator for 25 years. She currently serves on the editorial boards of the journal Health Affairs (rated as the top policy journal), Value in Health (a leading outcomes research journal), and all of the leading journals on personalized medicine. Kathryn has served on national and international scientific advisory committees and workshops including work Board of Directors for GenomeCanada, National Academy of Medicine, Food and Drug Administration, Centers for Disease Control and Prevention, and the President’s Council of Advisors on Science and Technology. She has also served as an advisor to various international and industry organizations, including more than 35 biotechnology companies and venture capital firms. She was recently awarded a Rockefeller Foundation global and worked with thethe Patient-Centered Outcomes Research Institute (PCORI) – the largest funder of comparative effectiveness research in the world – developing a research agenda on personalized/precision medicine.
M. Arthur Moseley, Ph.D.
Associate Research Professor Director, Duke Proteomics Core Facility, Duke University
Arthur Moseley is the Director of Proteomics and Metabolomics for the School of Medicine at Duke University. He holds leadership positions in the Center for Genomic and Computational Biology and the Center for Applied Genomics and Precision Medicine. At Duke, he is responsible for the development and application of proteomic and metabolomics technologies for open (unbiased) qualitative and quantitative UPLC/MS/MS analyses using high resolution, accurate mass tandem mass spectrometers coupled with ultra-performance nanoscale capillary liquid chromatographs, and for targeted quantitation using UPLC/MS/MS with multiple reaction monitoring (MRM).
The Proteomics and Metabolomics Shared Resource has the variety of capabilities for support of a diverse range of basic research projects, and the capacity for support of clinical trials. The clinical support has included biomarker discovery in studies in the areas of neurology, oncology, immunology, and infectious disease. Prior to his position at Duke University, he managed mass spectrometry laboratories at GSK for sixteen years, and for the last six years of these years he lead a transnational laboratory (US/UK) dedicated to proteomic biomarker discovery. Dr. Moseley received his MS in Physical Chemistry from North Carolina State University, and his PhD in Analytical Chemistry from the University of North Carolina at Chapel Hill. His dissertation, under the direction of Professor Jim Jorgenson, addressed the coupling of nanoscale separation with tandem mass spectrometry for the analysis of peptides and proteins.
Marian Rewers, MD, Ph.D.
Professor of Pediatrics and Medicine Executive Director, Barbara Davis Center for Childhood Diabetes, University of Colorado School of Medicine
Dr. Rewers is a pediatric endocrinologist who has dedicated his research to finding the cause and prevention of type 1 diabetes (T1D). His clinical team serves 7000 children and adults with T1D. His research is based on NIH-funded cohort studies: Diabetes Autoimmunity Study in the Young (DAISY) and The Environmental Determinants of Diabetes in the Young (TEDDY) following over 11,000 high-risk infants to learn how genes and the environment interact in causation of T1D and celiac disease. The Autoimmunity Screening for Kids (ASK) program is now translating findings from DAISY and TEDDY to public health screening for and prevention of T1D and celiac disease. In the Coronary Artery Calcification in Type 1 (CACTI) study, his team has discovered a number of novel genetic, metabolic, and inflammatory factors of potential importance for prevention of diabetic complications. Dr. Rewers has helped to train the next generation of investigators in clinical and translational research, including a number of pediatric endocrinologists. Together, they have published more than 400 original articles and reviews in the area of diabetes. Together, they have published more than 450 research articles and reviews in the area of diabetes.
Rohit Loomba, M.D.
Gastroenterologist and Hepatologist Vice Chief, Gastroenterology Director, Hepatology Professor of Medicine
Rohit Loomba, MD, is a board-certified gastroenterologist. His expertise includes treating and managing many types of chronic liver disease, such as nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis, chronic hepatitis, cirrhosis, and hemochromatosis. As a transplant hepatologist, Dr. Loomba works with transplant surgeons in the pre and postoperative care of liver transplant patients. He also directs the NAFLD Research Center at UC San Diego, and leads a multidisciplinary group of investigators to study NAFLD.
Dr. Loomba believes in providing compassionate and state-of-the-art care to his patients. He also believes in the importance of strong physician-patient relationships for improving medical decision making and delivering high quality care in a friendly environment.
As a professor in the Division of Gastroenterology, Dr. Loomba instructs students, residents and fellows in the Department of Medicine at UC San Diego School of Medicine. His research focuses on all aspects of NAFLD, including prevalence in aging, epidemiology, genetic and environmental predisposition and progression.
An advocate of evidenced-based medicine, Dr. Loomba has led numerous clinical trials to help find innovative treatments for people suffering from liver illness. He also serves as the director of the Nonalcoholic Steatohepatitis (NASH) Clinical Research Network at UC San Diego. Sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases, the NASH Clinical Research Network aims to facilitate and perform clinical, epidemiological and therapeutic research in nonalcoholic steatohepatitis.
Dr. Loomba is widely published, having co-authored more than 150 articles. His work has appeared in Gastroenterology, Hepatology, and Clinical Gastroenterology and Hepatology, among others. He also reviews for many journals, including Annals of Internal Medicine, Gastroenterology, The American Journal of Gastroenterology, and several others.
Dr. Loomba completed a fellowship in gastroenterology at UC San Diego School of Medicine and a fellowship in hepatology at the National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDKD) in Betheseda, M.d. He completed a residency in internal medicine at St. Luke’s Hospital in St. Louis. While in residency, he was selected for his clinical and leadership abilities to serve as chief resident. Dr. Loomba earned his medical degree from the Armed Forces Medical College in Pune, India. He obtained a Master of Health Science in clinical research from Duke University School of Medicine in Durham, N.C. Dr. Loomba is board-certified in internal medicine and gastroenterology.
He is a member of numerous professional societies, including the American Association for the Study of Liver Diseases, the American Gastroenterology Association, and the American Society for Gastrointestinal Endoscopy, among others.
Wayne W. Grody, M.D., Ph.D
Professor in the Departments of Pathology & Laboratory Medicine, Pediatrics, and Human Genetics, and the Institute for Society and Genetics, at the UCLA School of Medicine
Wayne W. Grody, M.D., Ph.D. is a Professor in the Departments of Pathology & Laboratory Medicine, Pediatrics, and Human Genetics, and the Institute for Society and Genetics, at the UCLA School of Medicine. He is the director of the Molecular Diagnostic Laboratories and the Clinical Genomics Center within the UCLA Medical Center, one of the first such facilities in the country to offer DNA-based tests for diagnosis of a wide variety of genetic, infectious, and neoplastic diseases, as well as bone marrow engraftment, patient specimen identification and paternity testing by DNA fingerprinting, and clinical genomic DNA sequencing for undiagnosed disorders. He is also an attending physician in the Department of Pediatrics, specializing in the care of patients with or at risk for genetic disorders (with a special interest in familial Mediterranean fever, among others), and director of the UCLA Intercampus Medical Genetics Training Program. In addition, he is heavily involved in basic molecular genetics research involving regulation of gene expression of arginase and related enzymes in hereditary arginase deficiency and various cancers, population molecular genetic screening, and construction of artificial human mutation samples. He has been one of the primary developers of quality assurance and ethical guidelines for DNA-based genetic testing for a large number of governmental and professional agencies including the FDA, AMA, CAP, ACMG, ASHG, NCCLS/CLSI, CDC, AMP, VA, ACGME, and the NIH-DOE Human Genome Project (ELSI program). He served as a member of the NIH-DOE Task Force on Genetic Testing, and was the working group chair for development of national guidelines for cystic fibrosis and factor V-Leiden mutation screening. He served for five years as founding chair of the Advisory Committee on Genomic Medicine for the entire VA healthcare system, and is Past President of the American College of Medical Genetics. Recent awards include the Lifetime Achievement Award from the College of American Pathologists, the Ward Burdick Award for Distinguished Service from the American Society for Clinical Pathology, the Bowes Award Lectureship at Harvard Medical School, the Roscher Endowed Lectureship of the International College of Surgeons, the Leadership Award from the Association for Molecular Pathology, and the Golden Apple Teaching Award from the UCLA Intercampus Medical Genetics Training Program. As a sidelight, Dr. Grody has been active in the film and television industries for many years, first as film critic for MD Magazine, a national leisure journal for physicians, then as technical advisor and sometime writer for a number of feature films, TV movies, and television series including Life Goes On, Chicago Hope, CSI, Medium, Law and Order, Heroes, and both Nutty Professor movies. He did his undergraduate work at Johns Hopkins University, received his M.D. and Ph.D. at Baylor College of Medicine, and completed residency and fellowship training at UCLA. He is double-board-certified by the American Board of Pathology (Anatomic and Clinical Pathology, Molecular Genetic Pathology) and the American Board of Medical Genetics (Clinical Genetics, Molecular Genetics, Biochemical Genetics).
Wainright Fishburn, JD
Partner – Cooley, LLP
M. Wainwright Fishburn, Jr. is a founding partner of Cooley’s San Diego office and a prominent venture capital lawyer. Wain’s practice emphasizes general representation of life science, technology and other operating companies that range from startup through IPO. His practice focuses on corporate governance
matters as well as mergers, acquisitions, strategic alliances, and intellectual property licensing and management. He also assists his client companies in financing matters, often involving the placement of debt and equity securities.
As a recognized life science and digital health thought-leader, Wain is a frequent speaker at programs addressing industry issues, including a keynote at the 2014 and 2015 International CES Digital Health Summit, USC’s Body Computing Conference, Impact Forum and the Wireless-Life Sciences Alliance’s
Convergence Summit. Wain has also served as Co-Chair of the BIO Digital Health Forum at the BIO International Convention from 2014-2016. As a community leader, Wain is immediate past Chairman of the Sanford-Burnham Institute for Medical Research, one of the nation’s leading independent biomedical research institutes. He recently joined The Executive Committee of the Board of the UCSD Moores Cancer Center where he is afforded a clinical perspective for the application of breakthroughs in genomic medicine and serves as on the organizing committee for the Center for Personalized Cancer Therapy. He serves as Vice Chair of the Critical Path Institute, an independent, non-profit organization dedicated to bringing scientists from the FDA. He is a founding director of both the Corporate Directors Forum and BIOCOM, the largest regional life science association in the world, representing more than 550 member companies and is a member of its Executive Committee
Patrick Lilley, MBA
Chief Data Scientist, Liquid Biosciences
Liquid Biosciences’ mission is to make healthcare more effective and less expensive, with fewer harmful effects. The company’s bio-inspired signal processing technology is used to predict treatment response, disease progression, and adverse events, as well as for diagnostics and multi-omics biomarker discovery. The company’s customers include pharmaceutical companies and healthcare service organizations. Patrick has spent the last 25 years driving growth and innovation in biotech, software, high-performance computing, and mobile wireless. He holds patents in artificial intelligence, disease prognosis, and specialized algorithms. He has guest lectured at CalTech, MIT, Stanford, Berkeley, USC, Brandman University, and UC Irvine. He holds a BA in Economics and an MBA specializing in quantitative finance, both from UC Irvine.
James C. Robinson, Ph.D., MPH
Leonard D. Schaeffer Professor of Health Economics, Director, Berkeley Center for Health Technology, Division Head, Health Policy and Management
School of Public Health, University of California
James Robinson is Leonard D. Schaeffer Professor of Health Economics and Director of the Berkeley Center for Health Technology (BCHT) at the University of California at Berkeley. He serves on a variety of professional boards and advisory boards, including the Integrated Healthcare Association and National Institute for Health Care Management, and as contributing editor for Health Affairs journal. Professor Robinson gives numerous keynote speeches and board presentations for medical technology firms, health insurance plans, hospitals, medical groups, universities, and public agencies.
At Berkeley, Professor Robinson’s research focuses on the biotechnology, medical device, insurance, and health care delivery sectors. He has published three books and over 130 papers in peer-reviewed journals such as the New England Journal of Medicine, JAMA, and Health Affairs. His most recent book, “Purchasing Medical Innovation: The Right Technology for the Right Patient at the Right Price” analyzes the roles of the FDA, health insurers, hospitals, and consumers in the assessment, purchasing, and use of high-cost implantable devices. Professor Robinson’s econometric research currently centers on the impact of reference pricing on consumer choices and employer spending for surgical procedures, laboratory tests, diagnostic imaging, and pharmaceuticals.
V.P. Payer Innovation, Alva 10
Lena has spent her career studying reimbursement and the managed care industry from the perspective of diagnostics. She believes that reimbursement, as one of the most misunderstood and dynamic aspects of healthcare, is ripe for innovation.
Leveraging her background in biology and mathematics, Lena is working to match the price of new diagnostics to payer value through improvements in the reimbursement process. Lena most recently led the reimbursement strategy of QIAGEN’s global molecular diagnostics portfolio and has broad experience in diagnostics commercialization, sales, contracting, and reimbursement. Earlier, she held multiple leadership roles at AmniSure International until its successful strategic sale. She has personally performed every step in the reimbursement spectrum of a diagnostic, and takes both a product-specific and portfolio-wide view of the healthcare products she brings to payers. She is passionate about driving reimbursement toward value-based care, and bringing clarity and change to a field that healthcare reform has put into flux.
Senior Solutions Architect, Intel Corporation
Andy Bartley is a Senior Solutions Architect in the Health & Life Sciences Organization at Intel Corporation. His focus areas are client technology and predictive analytics for healthcare providers. In his role Andy serves as a trusted adviser to stakeholders across the care continuum to aid in the development of leading-edge technology solutions that improve the provider and patient experience and enable healthcare delivery systems to deliver new models of care.
Andy has a diverse background in healthcare including senior operations roles at Stryker, VP of Business Development for One Medical Group and as Co-founder of Algorithms.io and NurseGrid. He is a regular speaker on the topic of innovation and is active in developing entrepreneurial communities in emerging markets .
Mitsuyuki “Mickey” Matsumoto, Ph.D.
Executive Director, Candidate Discovery Science Labs, Astellas Pharma
Dr. Matsumoto currently heads the Unit 2, Candidate Discovery Science Labs. at Astellas Pharma Inc. located in Tsukuba, Japan and is responsible for discovery of new therapeutics for neuropsychiatric and immune disorders. Dr. Matsumoto received his B.S. (1988), M.S. (1990) and Ph.D. (1997) from the University of Tokyo. After joining Astellas predecessor Yamanouchi Pharmaceutical Co, Ltd. in 1990, he led the G-protein coupled receptor (GPCR) group in discovering novel GPCRs and their ligands. Dr. Matsumoto served as a Visiting Scholar (2001 – 2003) at the National Institute of Mental Health (NIMH), USA, under Drs. Daniel Weinberger and Joel Kleinman, where he was involved in dedicated studies of schizophrenia genetics and pathophysiology. After Astellas Pharma Inc. emerged from a merger of Yamanouchi and Fujisawa, Dr. Matsumoto established a CNS research group at Astellas Research Institute of America LLC in Skokie, Illinois (2008 – 2014). In 2012, Dr. Matsumoto was the first member of the Japanese pharmaceutical industry nominated as a member of American College of Neuropsychopharmacology (ACNP). He has served as an Adjunct Professor at Northwestern University, USA (2009-2017).
Gerard Marek, MD, Ph.D.
Global Medical Lead, Astellas Pharma
Gerard Marek earned his MD and PhD (Psychopharmacology) at the University of Chicago in 1989 and 1988. After completing residency training in Psychiatry at the Yale University in the School of Medicine, he spent another 3 years as a post-doctoral fellow studying single cell electrophysiological recordings in rat brain slices. He then obtained independent RO1 funding after securing a junior faculty position in the Yale Department of Psychiatry in 1997 combining slice electrophysiology with independent neurochemical and behavioral studies. In January 2002, Gerard joined the Pfizer early clinical development group in Groton working on antidepressants and antipsychotic drugs. He moved to Eli Lilly in Oct 2003 and spent the majority of 5 years at Lilly leading a Discovery group in Psychiatric Disorders targeting novel antidepressants, antipsychotics, novel treatments for substance abuse and sleep disorders. Gerard then spent 6 years in Neuroscience Clinical Development at AbbVie mostly directed toward developing medications for the symptomatic treatment of Alzheimer’s disease and disease progression of multiple sclerosis with respect to remyelination and neurite sprouting. He moved to Astellas a little over 3 years ago where he has been leading programs studying cognitive impairment associated with schizophrenia and chronic pain syndromes.
William Potter, MD, Ph.D.
Senior Advisor to the NIMH
Dr. Potter earned his B.A., M.S., M.D., and Ph.D. at Indiana University, after which he held positions of increasing responsibility and seniority over the next 25 years at the National Institutes of Health (NIH) focused on translational neuroscience. Currently he serves as a Senior Advisor to the NIMH Director. Earlier at the NIH, Dr. Potter was widely published and appointed to many societies, committees, and boards; a role which enabled him to develop a wide reputation as an expert in psychopharmacological sciences and champion the development of novel treatments for central nervous system (CNS) disorders. Dr. Potter left the NIH in 1996 to accept a position as Executive Director and Research Fellow at Lilly Research Labs, specializing in the neuroscience therapeutic area and in 2004 joined Merck Research Labs as Vice President of Clinical Neuroscience, then the newly created position of Translational Neuroscience in 2006. His experience at Lilly and MRL in identifying, expanding, and developing methods of evaluating CNS effects of compounds in human brain cover state-of-the-art approaches across multiple modalities. These include brain imaging and cerebrospinal fluid proteomics (plus metabolomics) as well as development of more sensitive clinical, psychophysiological, and performance measures allowing a range of novel targets to be tested in a manner that actually addresses the underlying hypotheses. He has become a widely recognized champion for the position that more disciplined hypothesis testing of targets in humans is the best near term approach to moving CNS drug development forward. He has authored more than 200 publications in the field of preclinical and clinical pharmacology, mostly focused on drugs used in affective illnesses and methods for evaluating drug effects in humans. He has received many honors during his career, including the 1975–1977 Falk Fellow, American Psychiatric Association; 1986 Meritorious Service Medal, U.S. Public Health Service; and, in 1990, St. Elizabeth’s Residency Program Alumnus of the Year Award.
Pamila Brar, MD
Medical Director, Human Longevity Health Nucleus
Dr. Pamila Brar joined the HLI team in July 2015 as Medical Director of the Health Nucleus. Pam graduated from LSU Medical School in 1995 at age 23, and moved to San Diego to complete her Internal Medicine training. She was awarded the title of Ellen Browning Scripps Chief Medical Resident at Scripps Clinic La Jolla in 1999. After serving several years as a Scripps Clinic concierge physician, she started her own concierge medical practice in La Jolla in 2009 where she thrived.
Active in the American Academy of Private Physicians, a national organization dedicated to private medicine and healthcare innovation, Pam became an AAPP conference speaker, board member, and then served as the organization’s president from April 2015 to 2017. In recent years, Pam appeared regularly as a health consultant on San Diego news stations and honed her skills in communication. Despite her success in private practice, Pam’s love for science led her to join HLI in May 2015 as Medical Director of the Health Nucleus. This endeavor has allowed her to leverage her private medicine, leadership and business modeling experience to collaboratively grow a disruptive health intelligence delivery model. Utilizing whole genome sequencing, advanced imaging and omics, the Health Nucleus is a pioneer in the field of early detection and personalized medicine. The opportunity to collaborate with scientific visionaries including Craig Venter and Karen Nelson has been among the highlights of Pam’s career.
Ralph Riley, MBA
Co Dx Market Access Leader for the Co Diagnostic Commercial Strategy Group in Janssen Global Services
Ralph Riley, MBA is the Co Dx Market Access Leader for the Co Diagnostic Commercial Strategy Group in Janssen Global Services. He provides leadership in support of development, commercialization and policy related to companion and standalone “complementary” diagnostics in the areas of oncology, neuroscience, infectious disease, cardiovascular/metabolic disease and immunology. He has more than twenty-years of experience (twelve- years with J&J) in pharmaceutical, medical devices and diagnostics industries including tenure in sales, marketing, analytics and market access.
Ralph has co-authored several papers articulating the value of diagnostics and personalized medicine, lead research in epidemiology and modeling the use of bio-markers for chronic disease and has spoken at many personalized medicine and access focused conferences regarding opportunities for evidence generation and access strategy related to testing.